Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 26, 1996 - Issue 3
Submit an article Journal homepage
113
Views
49
CrossRef citations to date
0
Altmetric
Research Article

Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes

W. Jaeger Department of Pharmacy, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA, 32, USA
,
L. Z. Benet Department of Pharmacy, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA, 32, USA
&
L. M. Bornheim Department of Pharmacology, University of California, San Francisco, 513 Parnassus Avenue, S-1210, Box 0450, San Francisco, CA, 32, USA
Pages 275-284 | Received 05 Aug 1995, Published online: 22 Sep 2008

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Franjo Grotenhermen. (2004) Clinical Pharmacodynamics of Cannabinoids. Journal of Cannabis Therapeutics 4:1, pages 29-78.
Read now
Franjo Grotenhermen. (2003) Clinical Pharmacokinetics of Cannabinoids. Journal of Cannabis Therapeutics 3:1, pages 3-51.
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Slobodan Rendic & Frederick J. Di Carlo. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors. Drug Metabolism Reviews 29:1-2, pages 413-580.
Read now

Articles from other publishers (45)

Claudia Stöllberger & Josef Finsterer. (2023) Cannabidiol's impact on drug-metabolization. European Journal of Internal Medicine 118, pages 6-13.
Crossref
Min-zheng Zhu, Mei-feng Yang, Yang Song, Hao-ming Xu, Jing Xu, Ning-ning Yue, Yuan Zhang, Cheng-mei Tian, Rui-yue Shi, Yu-jie Liang, Jun Yao, Li-sheng Wang, Yu-qiang Nie & De-feng Li. (2023) Exploring the efficacy of herbal medicinal products as oral therapy for inflammatory bowel disease. Biomedicine & Pharmacotherapy 165, pages 115266.
Crossref
Clémence Lacroix, Romain Guilhaumou, Joëlle Micallef & Olivier Blin. (2023) Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox. Therapies.
Crossref
Jorge Luis Sotelo & Melanie Bilbul. 2022. Transplant Psychiatry. Transplant Psychiatry 167 176 .
Claude Cyr, Mellar P. Davis, Danial Schecter & Paul DaeninckDanial Schecter & Claude Cyr. 2022. Cannabis and Cannabinoid-Based Medicines in Cancer Care. Cannabis and Cannabinoid-Based Medicines in Cancer Care 153 190 .
Andrew Charrette, James Akingbasote, Najla Guthrie & Corey J. Hilmas. 2021. Nutraceuticals. Nutraceuticals 625 659 .
Greg Copas, Erik Amazonas & Sarah Brandon. 2021. Cannabis Therapy in Veterinary Medicine. Cannabis Therapy in Veterinary Medicine 17 59 .
Philip N. Patsalos, Jerzy P. Szaflarski, Barry Gidal, Kevan VanLandingham, David Critchley & Gilmour Morrison. (2020) Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia 61:9, pages 1854-1868.
Crossref
Joshua L. Rein. (2020) The nephrologistʼs guide to cannabis and cannabinoids. Current Opinion in Nephrology and Hypertension 29:2, pages 248-257.
Crossref
Samira S. Farouk & Joshua L. Rein. (2020) The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?. Advances in Chronic Kidney Disease 27:1, pages 56-66.
Crossref
Grainne Holleran, Franco Scaldaferri, Antonio Gasbarrini & Diego Currò. (2019) Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double‐blind randomised controlled trials. Phytotherapy Research 34:1, pages 77-93.
Crossref
Abbie D. Leino, Chie Emoto, Tsuyoshi Fukuda, Michael Privitera, Alexander A. Vinks & Rita R. Alloway. (2019) Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation 19:10, pages 2944-2948.
Crossref
Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier & Francesco Paolo Busardò. (2019) Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology 17:10, pages 974-989.
Crossref
Emily J. Cox, Neha Maharao, Gabriela Patilea-Vrana, Jashvant D. Unadkat, Allan E. Rettie, Jeannine S. McCune & Mary F. Paine. (2019) A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. Pharmacology & Therapeutics 201, pages 25-38.
Crossref
Marilyn E. Levi, Brian T. Montague, Christian Thurstone, Deepali Kumar, Shirish S. Huprikar & Camille N. Kotton. (2019) Marijuana use in transplantation: A call for clarity. Clinical Transplantation 33:2, pages e13456.
Crossref
Nicholas Z. Greene, Jenny L. Wiley, Zhihao Yu, Brian H. Clowers & Rebecca M. Craft. (2018) Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol. Psychopharmacology 235:11, pages 3289-3302.
Crossref
Yu Xie, Deanna Dilibero & David H. Chang. (2018) Review of Major Drug-Drug Interactions in Thoracic Transplantation. Current Transplantation Reports 5:3, pages 220-230.
Crossref
William R. Arnold, Austin T. Weigle & Aditi Das. (2018) Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2. Journal of Inorganic Biochemistry 184, pages 88-99.
Crossref
Joshua L. Rein & Christina M. Wyatt. (2018) Marijuana and Cannabinoids in ESRD and Earlier Stages of CKD. American Journal of Kidney Diseases 71:2, pages 267-274.
Crossref
Stevie C. Britch, Jenny L. Wiley, Zhihao Yu, Brian H. Clowers & Rebecca M. Craft. (2017) Cannabidiol-Δ 9 -tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug and Alcohol Dependence 175, pages 187-197.
Crossref
. (2015) Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. EFSA Journal 13:6.
Crossref
Sean D. McAllister, Liliana Soroceanu & Pierre-Yves Desprez. (2015) The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology 10:2, pages 255-267.
Crossref
Satoshi Yamaori, Yoshimi Okushima, Ikuo Yamamoto & Kazuhito Watanabe. (2014) Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chemico-Biological Interactions 215, pages 62-68.
Crossref
D. Colombo, L. Lunardon & G. Bellia. (2014) Cyclosporine and Herbal Supplement Interactions. Journal of Toxicology 2014, pages 1-6.
Crossref
Rongrong Jiang, Satoshi Yamaori, Yasuka Okamoto, Ikuo Yamamoto & Kazuhito Watanabe. (2013) Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics 28:4, pages 332-338.
Crossref
Satoshi Yamaori, Yoshimi Okushima, Kazufumi Masuda, Mika Kushihara, Takashi Katsu, Shizuo Narimatsu, Ikuo Yamamoto & Kazuhito Watanabe. (2013) Structural Requirements for Potent Direct Inhibition of Human Cytochrome P450 1A1 by Cannabidiol: Role of Pentylresorcinol Moiety. Biological and Pharmaceutical Bulletin 36:7, pages 1197-1203.
Crossref
Michael Murray. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics 517 542 .
Satoshi Yamaori, Yasuka Okamoto, Ikuo Yamamoto & Kazuhito Watanabe. (2011) Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6. Drug Metabolism and Disposition 39:11, pages 2049-2056.
Crossref
Satoshi Yamaori, Chikako Maeda, Ikuo Yamamoto & Kazuhito Watanabe. (2011) Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicology 29:2, pages 117-124.
Crossref
Satoshi Yamaori, Juri Ebisawa, Yoshimi Okushima, Ikuo Yamamoto & Kazuhito Watanabe. (2011) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sciences 88:15-16, pages 730-736.
Crossref
Satoshi Yamaori, Mika Kushihara, Ikuo Yamamoto & Kazuhito Watanabe. (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochemical Pharmacology 79:11, pages 1691-1698.
Crossref
Audra L Stinchcomb, Satyanarayana Valiveti, Dana C Hammell & Diana R Ramsey. (2004) Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. Journal of Pharmacy and Pharmacology 56:3, pages 291-297.
Crossref
Walter Jäger, Marion Mayer, Peter Platzer, Gottfried Reznicek, Hermann Dietrich & Gerhard Buchbauer. (2000) Stereoselective Metabolism of the Monoterpene Carvone by Rat and Human Liver Microsomes. Journal of Pharmacy and Pharmacology 52:2, pages 191-197.
Crossref
Kazuhide Hayakawa, Kenichi Mishima, Mai Hazekawa, Kazunori Sano, Keiichi Irie, Kensuke Orito, Takashi Egawa, Yoshihisa Kitamura, Naoki Uchida, Ryoji Nishimura, Nobuaki Egashira, Katsunori Iwasaki & Michihiro Fujiwara. (2008) Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism. Brain Research 1188, pages 157-164.
Crossref
Gisela Skopp, Peter Strohbeck-Kuehner, Karl Mann & Derik Hermann. (2007) Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Science International 170:1, pages 46-50.
Crossref
Frederike K. Engels, Floris A. de Jong, Alex Sparreboom, Ron A. A. Mathot, Walter J. Loos, Jos J. E. M. Kitzen, Peter de Bruijn, Jaap Verweij & Ron H. J. Mathijssen. (2007) Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. The Oncologist 12:3, pages 291-300.
Crossref
S. A. Varvel, J. L. Wiley, R. Yang, D. T. Bridgen, K. Long, A. H. Lichtman & B. R. Martin. (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186:2, pages 226-234.
Crossref
FTA Pijlman, SM Rigter, J Hoek, HMJ Goldschmidt & RJM Niesink. (2005) Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology 10:2, pages 171-180.
Crossref
Salah A. Sheweita. (2003) Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Toxicology 191:2-3, pages 133-142.
Crossref
Franjo Grotenhermen. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics 42:4, pages 327-360.
Crossref
Raphael Mechoulam & Lumı́r Hanuš. (2002) Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chemistry and Physics of Lipids 121:1-2, pages 35-43.
Crossref
Bradley W. Kosel, Francesca T. Aweeka, Neal L. Benowitz, Starley B. Shade, Joan F. Hilton, Patricia S. Lizak & Donald I. Abrams. (2002) The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:4, pages 543-550.
Crossref
Leo E. Hollister. 1999. Marihuana and Medicine. Marihuana and Medicine 273 277 .
Marilyn Huestis. 1999. Marihuana and Medicine. Marihuana and Medicine 105 116 .
David J. Harvey. 1999. Marihuana and Medicine. Marihuana and Medicine 91 103 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.